Showing results (71-80 of 439) with videos related to
Sort By:
Pageof 44
Molecular Biology of the Cell|March 18, 2016
Tension on JAM-A activates RhoA via GEF-H1 and p115 RhoGEFDavid W Scott, Caitlin E Tolbert, Keith BurridgeAnnual Review of Pathology|October 16, 2025
Genomic Taxonomy of Aggressive B-Cell Lymphoid NeoplasmsLaura K Hilton, Brett Collinge, David W ScottAmerican Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 1, 2018
Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARsAntoine Sicard, Megan K Levings, David W ScottCellular Immunology|August 16, 2005
Tolerance induction via a B-cell delivered gene therapy-based protocol: optimization and role of the Ig scaffoldTie Chi Lei, Yan Su, David W ScottInfection and Immunity|May 7, 2008
Francisella tularensis subsp. tularensis Schu S4 disulfide bond formation protein B, but not an RND-type efflux pump, is required for virulenceAiping Qin, David W Scott, Barbara J MannInfectious Disorders Drug Targets|March 8, 2012
B-cell based gene therapy for autoimmune diseasesDavid W Scott, Ai-Hong Zhang, Yan SuBlood|June 27, 2012
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.Blood|August 6, 2005
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosisMargaret E Tome, David B F Johnson, Lisa M Rimsza, et al.Leukemia & Lymphoma|April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.Pain|August 1, 1993
Characteristics of chronic pain patients: factor analysis of the MMPI-2William W Deardorff, Allan F Chino, David W ScottPageof 44